Siyuan Le

Summary

Affiliation: Cephalon Inc
Country: USA

Publications

  1. doi request reprint Correlation between ex vivo receptor occupancy and wake-promoting activity of selective H3 receptor antagonists
    Siyuan Le
    World Wide Discovery Research, CNS Biology, Cephalon, Inc, 145 Brandywine Parkway, West Chester, PA 19380, USA
    J Pharmacol Exp Ther 325:902-9. 2008
  2. doi request reprint Detection of low level histamine H3 receptor occupancy by autoradiography
    Siyuan Le
    World Wide Discovery Research, Cephalon, Inc, West Chester, PA 19380, USA
    J Neurosci Methods 185:70-5. 2009
  3. doi request reprint CEP-26401 (irdabisant), a potent and selective histamine H₃ receptor antagonist/inverse agonist with cognition-enhancing and wake-promoting activities
    Rita Raddatz
    Cephalon, Inc, 145 Brandywine Parkway, West Chester, PA 19380, USA
    J Pharmacol Exp Ther 340:124-33. 2012

Detail Information

Publications3

  1. doi request reprint Correlation between ex vivo receptor occupancy and wake-promoting activity of selective H3 receptor antagonists
    Siyuan Le
    World Wide Discovery Research, CNS Biology, Cephalon, Inc, 145 Brandywine Parkway, West Chester, PA 19380, USA
    J Pharmacol Exp Ther 325:902-9. 2008
    ..Robust waking activity at higher levels of H3R occupancy may be mechanistically different from activities at low levels of H3R occupancy...
  2. doi request reprint Detection of low level histamine H3 receptor occupancy by autoradiography
    Siyuan Le
    World Wide Discovery Research, Cephalon, Inc, West Chester, PA 19380, USA
    J Neurosci Methods 185:70-5. 2009
    ..Furthermore, the increased sensitivity should be useful in providing dosing guidelines for H(3) antagonists in both preclinical and clinical settings...
  3. doi request reprint CEP-26401 (irdabisant), a potent and selective histamine H₃ receptor antagonist/inverse agonist with cognition-enhancing and wake-promoting activities
    Rita Raddatz
    Cephalon, Inc, 145 Brandywine Parkway, West Chester, PA 19380, USA
    J Pharmacol Exp Ther 340:124-33. 2012
    ..CEP-26401 may also have therapeutic utility in treating schizophrenia or as adjunctive therapy to approved antipsychotics...